A Phase 1 interventional study of aripiprazole IM depot and aripiprazole tablets in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-01-22.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 98th largest by enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 1, and was the 78th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 88th largest by enrollment of the 111 interventional ones that give a count, is one of 2 that started in 2007, is one of 34 in phase 1, and was the 53rd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
Drug: aripiprazole IM depot · Drug: aripiprazole tablets
300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
Drug: aripiprazole IM depot · Drug: aripiprazole tablets
200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
Drug: aripiprazole IM depot · Drug: aripiprazole tablets
Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
Aripiprazole tablets 10 mg once daily in the morning for 14 days.
Number of Participants With Adverse Events as a Measure of Safety
Safety and tolerability was assessed by the number of participants with adverse events (AE). An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject while enrolled in the study, whether or not it was considered drug-related by the investigator. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (ie, clinically significant) change from baseline for that individual participant.
Time frame: 7 Months
Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,min were determined directly from the observed data at 672 hours after the fifth monthly injection.
Time frame: 672 hours post-dose at Month 5
Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Aripiprazole Steady-state Plasma Concentration (Css,Avg)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,avg were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Aripiprazole Terminal-phase Elimination Half-life (t1/2,z)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for t1/2,z were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,min were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 and Week 24
The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12, Week 24
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Positive Subscale Scores at Week 12 and Week 24
The PANSS Positive Subscale consisted of 7 symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12, Week 24
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Subscale Scores at Week 12 and Week 24
The PANSS Negative Subscale consisted of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12, Week 24
Change From Baseline in the Clinical Global Impression- Severity of Illness Score (CGI-S) at Week 12 and Week 24
The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12, Week 24
Clinical Global Impression-Improvement Scale (CGI-I) at Week 12 and Week 24
The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.
Time frame: Baseline, Week 12, Week 24
Number of Participants Hospitalized for Adverse Event "Worsening Schizophrenia"
The number of participants hospitalized for the Adverse Event "Worsening Schizophrenia included all participants who were hospitalized for any Adverse Event pertaining to the exacerbation of schizophrenic symptoms.
Time frame: 7 Months
| Milestone | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Started | 14 | 16 | 11 |
| Safety population; received study drug | 14 | 15 | 10 |
| Completed | 10 | 8 | 4 |
| Not completed | 4 | 8 | 7 |
| Withdrew: Adverse event | 0 | 4 | 1 |
| Withdrew: Subject met withdrawal criteria | 3 | 2 | 0 |
| Withdrew: Subject withdrawn by investigator | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
Safety and tolerability was assessed by the number of participants with adverse events (AE). An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject while enrolled in the study, whether or not it was considered drug-related by the investigator. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (ie, clinically significant) change from baseline for that individual participant.
| Participants | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety | 11 | 11 | 6 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| ng/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Maximum Steady State Plasma Concentration (Css,Max) | 316 ± 160 | 269 ± 128 | 100 ± 68.4 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,min were determined directly from the observed data at 672 hours after the fifth monthly injection.
| ng/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Minimum Steady State Plasma Concentration (Css,Min) | 212 ± 113 | 156 ± 67.7 | 95.0 ± 86.2 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.
| μg*h/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ) | 163 ± 88.8 | 140 ± 58.4 | 54.5 ± 39.4 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| Day | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Maximum (Peak) Plasma Concentration (Tmax) | 7.1 (3.0 to 11.2) | 6.5 (0.5 to 21.2) | 5.0 (4.0 to 27.9) |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,avg were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| ng/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Steady-state Plasma Concentration (Css,Avg) | 242 ± 132 | 208 ± 87.0 | 81.1 ± 58.7 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for t1/2,z were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| Day | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Aripiprazole Terminal-phase Elimination Half-life (t1/2,z) | 46.5 ± 10.8 | 29.9 ± 8.0 | — |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| ng/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max) | 89.4 ± 37.9 | 74.7 ± 20.8 | 30.3 ± 19.8 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,min were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| ng/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min) | 64.1 ± 27.0 | 54.1 ± 21.1 | 26.2 ± 24.7 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.
| μg*h/mL | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ) | 47.8 ± 19.1 | 38.9 ± 13.2 | 14.7 ± 9.47 |
Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.
| Day | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax) | 6.6 (3.0 to 14.0) | 12.5 (0.5 to 22.2) | 5.5 (0.0 to 27.9) |
The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.
| units on a scale | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Week 12 | 0.0 ± 20.2 | 1.1 ± 12.1 | -1.3 ± 4.8 |
| Week 24 | -0.8 ± 20.9 | -1.6 ± 14.1 | -1.3 ± 5.3 |
The PANSS Positive Subscale consisted of 7 symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.
| units on a scale | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Week 12 | -1.2 ± 6.1 | 1.3 ± 4.0 | -1.0 ± 1.2 |
| Week 24 | -1.6 ± 6.1 | 0.4 ± 4.5 | -1.0 ± 1.6 |
The PANSS Negative Subscale consisted of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A negative change from Baseline indicated improvement.
| units on a scale | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Week 12 | 1.1 ± 4.4 | 0.1 ± 3.2 | 0.0 ± 2.0 |
| Week 24 | 0.5 ± 4.2 | -0.1 ± 3.7 | -0.6 ± 2.0 |
The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients. A negative change from Baseline indicated improvement.
| units on a scale | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Week 12 | -0.1 ± 0.5 | 0.0 ± 0.6 | -0.2 ± 0.4 |
| Week 24 | -0.1 ± 0.5 | -0.1 ± 0.7 | -0.2 ± 0.4 |
The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.
| units on a scale | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Week 12 (n=12, 13, 9) | 3.3 ± 0.9 | 3.6 ± 0.8 | 3.4 ± 0.7 |
| Week 24 | 3.7 ± 1.0 | 3.4 ± 0.7 | 3.7 ± 0.7 |
The number of participants hospitalized for the Adverse Event "Worsening Schizophrenia included all participants who were hospitalized for any Adverse Event pertaining to the exacerbation of schizophrenic symptoms.
| Participants | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Number of Participants Hospitalized for Adverse Event "Worsening Schizophrenia" | 0 | 1 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 mg Aripiprazole IM Depot | — | 0/14 (0%) | 9/14 (64.3%) |
| 300 mg Aripiprazole IM Depot | — | 3/15 (20%) | 10/15 (66.7%) |
| 200 mg Aripiprazole IM Depot | — | 0/10 (0%) | 6/10 (60%) |
| Event | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Chest PainGeneral disorders | 0/14 | 1/15 | 0/10 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/14 | 1/15 | 0/10 |
| Psychotic disorderPsychiatric disorders | 0/14 | 1/15 | 0/10 |
| SchizophreniaPsychiatric disorders | 0/14 | 1/15 | 0/10 |
| Event | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot |
|---|---|---|---|
| Injection site painGeneral disorders | 4/14 | 0/15 | 0/10 |
| TremorNervous system disorders | 3/14 | 1/15 | 0/10 |
| HeadacheNervous system disorders | 1/14 | 0/15 | 2/10 |
| VomitingGastrointestinal disorders | 2/14 | 2/15 | 0/10 |
| NasopharyngitisInfections and infestations | 2/14 | 1/15 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 2/14 | 1/15 | 1/10 |
| Muscle strainInjury, poisoning and procedural complications | 2/14 | 0/15 | 0/10 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 2/14 | 0/15 | 0/10 |
| SedationNervous system disorders | 2/14 | 0/15 | 0/10 |
| RashSkin and subcutaneous tissue disorders | 2/14 | 0/15 | 0/10 |
All participants randomized
| Age, Continuous(years) | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot | Total |
|---|---|---|---|---|
| Mean | 46.8 ± 9.2 | 43.3 ± 9.6 | 46.0 ± 12.7 | 45.2 ± 10.3 |
| Sex: Female, Male(Participants) | 400 mg Aripiprazole IM Depot | 300 mg Aripiprazole IM Depot | 200 mg Aripiprazole IM Depot | Total |
|---|---|---|---|---|
| Female | 7 | 4 | 1 | 12 |
| Male | 7 | 12 | 10 | 29 |
The record gives a start of Nov 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →